Lipocine Announces Financial and Operational Results for the Full Year of 2015
March 10, 2016 16:30 ET
|
Lipocine Inc.
SALT LAKE CITY, March 10, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial results for the full year ended December 31,...
Lipocine to Present at 28th Annual Roth Conference
March 08, 2016 08:00 ET
|
Lipocine Inc.
SALT LAKE CITY, March 08, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown,...
Lipocine Reports Positive Results of Multi-Dose Pharmacokinetic Study of LPCN 1107 for the Prevention of Preterm Birth in Pregnant Women
February 16, 2016 07:00 ET
|
Lipocine Inc.
Relevant hydroxyprogesterone caproate levels achieved following oral administrationAmenable to dose adjustment while on therapyWell tolerated with no serious adverse events or adverse drug reactions...
Lipocine Announces First Patient Dosed in Phase 2B Clinical Study for LPCN 1111, a Novel Testosterone Replacement Therapy
January 04, 2016 09:00 ET
|
Lipocine Inc.
SALT LAKE CITY, Jan. 04, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that the first patient has been dosed in its Phase 2b clinical...
Lipocine to Present at 27th Annual Piper Jaffray Healthcare Conference
November 24, 2015 09:00 ET
|
Lipocine Inc.
SALT LAKE CITY, Nov. 24, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown, Executive...
Lipocine Adopts Stockholder Rights Plan
November 13, 2015 16:00 ET
|
Lipocine Inc.
SALT LAKE CITY, Nov. 13, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that on November 12, 2015 its board of directors adopted a...
Lipocine Announces Financial and Operational Results for the Third Quarter of 2015
November 12, 2015 16:02 ET
|
Lipocine Inc.
SALT LAKE CITY, Nov. 12, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial results for the quarter ended September 30, 2015, as well...
Lipocine Announces PDUFA Goal Date for LPCN 1021 NDA
November 12, 2015 16:00 ET
|
Lipocine Inc.
SALT LAKE CITY, Nov. 12, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration ("FDA") has assigned a...
Lipocine Announces Presentation of LPCN 1021 Clinical Data at 21st Annual SMSNA Meeting
November 11, 2015 16:00 ET
|
Lipocine Inc.
SALT LAKE CITY, Nov. 11, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that clinical data for LPCN 1021, an oral testosterone product...
FDA Accepts for Filing Lipocine’s New Drug Application for Its Oral Testosterone Replacement Product Candidate, LPCN 1021
October 29, 2015 16:00 ET
|
Lipocine Inc.
SALT LAKE CITY, Oct. 29, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration ("FDA") has accepted...